Veracyte beats Q3 estimates but narrows full-year revenue outlook
+2 new sources since this summary was written
Veracyte reported third-quarter results after the Nov. 4 close, with revenue of $151.75M, up 15% year over year, and net income of $31.5M, or 38c/share. Adjusted EPS was 51 cents, while the company narrowed its 2026 revenue forecast to $590M-$593M from $590M-$596M. Decipher Prostate test volume grew 12% year over year but was approximately 1 thousand tests below expectations, prompting Veracyte to reset its incremental annual volume outlook.
Why it matters
The lower full-year outlook and slower-than-expected Decipher volume weakened the growth outlook despite the quarterly earnings beat. Veracyte said it plans to expand its urology team by 30% next year and expects incremental annual Decipher volume growth of 12 thousand to 15 thousand tests.
Key facts
- 1Veracyte reported third-quarter revenue of $151.75M, up 15% year over year, and net income of $31.5M, or 38c/share. rttnews.com
- 2Adjusted EPS was 51 cents. finance.yahoo.com
- 3The 2026 revenue forecast was narrowed to $590M-$593M from $590M-$596M. finance.yahoo.com
- 4Decipher Prostate delivered nearly 30 thousand tests, representing 12% year-over-year growth, with volume approximately 1 thousand tests below expectations. finance.yahoo.com
- 5Veracyte reset incremental annual Decipher volume growth expectations to 12 thousand to 15 thousand tests. finance.yahoo.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.